News

According to the company, full enrollment anticipated by first week of September. The phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign and symptom of DED.

We asked, "What research at ASRS 2023 do you find exciting or interesting?" Here's what Paul Hahn, MD, PhD, Kerrie Brady, BPharm, MBA, MS, and Michael Singer, MD had to say!

Advancements from Carl Zeiss Medical AG in the cataract and cornea space include a new intraocular lens and therapeutic laser enhancements.

Maria H. Berrocal, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium in Marco Island, Florida.

The trial will be conducted by French tissue bank, TBF Génie Tissulaire.

According to the Keck School of Medicine of USC, the $12.4 million from the California Institute for Regenerative Medicine is the latest round of support for USC researcher Mark Humayun and a milestone in the development of a stem cell patch to treat advanced dry age-related macular degeneration.

The new platform incorporates the SILK procedure, allowing surgeons to perform refractive correction on patients with myopia.

The EUREQUO Annual Report celebrates 15 years and over 4 million surgical procedures in the registry.

According to the company, it is working with the FDA to address the agency’s issues.

According to Outlook Therapeutics, it is working with the FDA to address the agency’s issues.

According to Outlook Therapeutics, it is working with the FDA to address the agency’s issues.

The study from New Zealand was conducted on an otherwise healthy 28-year-old woman.

Language can drive understanding, trust, and better outcomes for patients

Eva Kim, MD, spoke with our team to share insights from her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

According to the company, it is anticipating cost savings of up to $300 million through 2024, which includes an estimated 25% reduction in current workforce and a reduction in external expenses.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

OCT methods are invaluable in the assessment of patients with the condition

TOUR006 is an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED).

The organization says to stop using Dr. Berne’s and LightEyez MSM drops immediately due to bacterial contamination, fungal contamination, or both.

More than 135 patients have been recruited in 4 months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 ophthalmic solution as an adjunct to standard-of-care surgery.

For clinicians, the evolution of treatment is as much a responsibility as an opportunity.

Commonly used immunosuppressants used in the short term to control an ocular inflammatory disease were not associated with increased risk of developing cancer later.

The investigators performed a retrospective cohort study of patients from 10 US ocular inflammatory disease (OID) subspecialty practices.

Amber Bio is developing a first-of-its-kind RNA writing platform using multi-kilobase edits to reach previously undruggable patient populations.

Priya Vakharia, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.

Sruthi Arepalli, MD, spoke with our team about the current landscape of geographic atrophy (GA) and her presentation at the Women in Ophthalmology Summer Symposium being held in Marco Island, Florida.